Evidence map›Paper›PMID 15824059›Full record

ArticleNucleic acids research2005

NMR chemical shift and relaxation measurements provide evidence for the coupled folding and binding of the p53 transactivation domain.

Pamela D Vise, Bharat Baral, Andrew J Latos, Gary W Daughdrill

Open access · goldAbstract read
In one paragraph

Article in Nucleic acids research, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 105 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Structural diversity of p63 and p73 isoforms.Cell death and differentiation · 2022
    Review
  10. Article
  11. Review
  12. Article
  13. Tumor-Suppressor p53TADChembiochem : a European journal of chemical biology · 2020
    Article
  14. Targeting intrinsically disordered proteins involved in cancer.Cellular and molecular life sciences : CMLS · 2020
    Review
  15. Article
  16. Review
  17. Article
  18. Proteasome Activation to Combat Proteotoxicity.Molecules (Basel, Switzerland) · 2019
    Review
  19. Interaction between p53 N terminus and core domain regulates specific and nonspecific DNA binding.Proceedings of the National Academy of Sciences of the United States of America · 2019
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Pamela D ViseDepartment of Microbiology, Molecular Biology and Biochemistry, University of Idaho PO Box 443052, Life Science South Room 142, Moscow 83844-3052, Idaho, USA.
Bharat Baral
Andrew J Latos
Gary W Daughdrill
University of Idaho · US

Funding

UNDERGRADUATE COLLEGE OUTREACH PROGRAMP20RR016454 · NCRR · UNIVERSITY OF IDAHO · PI SIMPKIN, JANICE L · 2001 to 2011
$35.3M
The Evolution of Protein FlexibilityP20RR016448 · NCRR · UNIVERSITY OF IDAHO · PI FORNEY, LARRY J · 2002 to 2011
$19.3M
NCRR NIH HHS P20 RR016448NCRR NIH HHS P20 RR016454NCRR NIH HHS P20 RR 16448
6 · The paper itself

Abstract

The interaction between the acidic transactivation domain of the human tumor suppressor protein p53 (p53TAD) and the 70 kDa subunit of human replication protein A (hRPA70) was investigated using heteronuclear magnetic resonance spectroscopy. A 1H-15N heteronuclear single quantum coherence (HSQC) titration experiment was performed on a 15N-labeled fragment of hRPA70, containing the N-terminal 168 residues (hRPA701-168) and p53TAD. HRPA701-168 residues important for binding were identified and found to be localized to a prominent basic cleft. This binding site overlapped with a previously identified single-stranded DNA-binding site, suggesting that a competitive binding mechanism may regulate the formation of p53TAD-hRPA70 complex. The amide 1H and 15N chemical shifts of an uniformly 15N-labeled sample of p53TAD were also monitored before and after the addition of unlabeled hRPA701-168. In the presence of unlabeled hRPA701-168, resonance lineshapes increased and corresponding intensity reductions were observed for specific p53TAD residues. The largest intensity reductions were observed for p53TAD residues 42-56. Minimal binding was observed between p53TAD and a mutant form of hRPA701-168, where the basic cleft residue R41 was changed to a glutamic acid (R41E), demonstrating that ionic interactions play an important role in specifying the binding interface. The region of p53TAD most affected by binding hRPA701-168 was found to have some residual alpha helical and beta strand structure; however, this structure was not stabilized by binding hRPA701-168. 15N relaxation experiments were performed to monitor changes in backbone dynamics of p53TAD when bound to hRPA701-168. Large changes in both the transverse (R2) and rotating frame (R1) relaxation rates were observed for a subset of the p53TAD residues that had 1H-15N HSQC resonance intensity reductions during the complex formation. The folding of p53TAD upon complex formation is suggested by the pattern of changes observed for both R2 and R1. A model that couples the formation of a weak encounter complex between p53TAD and hRPA701-168 to the folding of p53TAD is discussed in the context of a functional role for the p53-hRPA70 complex in DNA repair.

Indexed as

Amino AcidsAmino Acid SequenceBinding SitesDNA-Binding ProteinsDNA, Single-StrandedHumansMolecular Sequence DataNuclear Magnetic Resonance, BiomolecularProtein FoldingProtein Structure, TertiaryReplication Protein ATrans-ActivatorsTumor Suppressor Protein p53Amino AcidsDNA-Binding ProteinsDNA, Single-StrandedReplication Protein ARPA1 protein, humanTrans-ActivatorsTumor Suppressor Protein p53

Identifiers

PMID15824059
PMCPMC1075921
OpenAlexW1992285513

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.